文献速递糖尿病性腺与生殖内分泌

中年期糖尿病与子宫肌瘤诊断:全国女性健康研究(SWAN)

Diabetes and Uterine Fibroid Diagnosis in Midlife: Study of Women's Health Across the Nation (SWAN).
PubMed 文献 · J Clin Endocrinol Metab · 2025-01-01

在全国女性健康研究(SWAN)队列(n=2570)中,前瞻性评估血糖、胰岛素、性激素结合球蛋白(SHBG)及糖尿病与中年期子宫肌瘤诊断的相关性。时变血糖、胰岛素、HOMA-IR及SHBG与肌瘤诊断无关;糖尿病与肌瘤诊断发生率降低28%相关(校正HR 0.72,95%CI 0.44-1.17),使用二甲双胍者校正HR 0.49(95%CI 0.21-1.12),但精度有限。绝经前HOMA-IR及胰岛素升高与肌瘤诊断发生率增加相关,糖尿病与肌瘤的负相关在围绝经期最强。

要点

  • 时变血糖、胰岛素、HOMA-IR及SHBG与子宫肌瘤诊断无关联。
  • 糖尿病与肌瘤诊断发生率降低28%相关(校正HR 0.72,95%CI 0.44-1.17)。
  • 绝经前HOMA-IR和胰岛素升高与肌瘤诊断发生率增加相关,围绝经期无此关联。

核心结论

  • 糖尿病及生物标志物对子宫肌瘤的影响可能因绝经状态而异。
  • 肌瘤风险可能随胰岛素抵抗增加而升高,随糖尿病治疗而降低。

研究设计与样本

  • 全国女性健康研究(SWAN)前瞻性队列,纳入2570名参与者。
  • 入组(1996-1997年)及13次随访(1996-2013年)报告子宫肌瘤诊断。
  • 所有访视检测空腹血糖、胰岛素及SHBG,计算HOMA-IR。
  • 糖尿病定义基于血糖水平、自报糖尿病或使用糖尿病药物。
  • 采用离散时间生存模型估计时变生物标志物及糖尿病与 incident 肌瘤诊断的风险比(HR)及95%CI,校正人口学特征及医疗利用。

主要发现

  • 基线时2.7%的参与者(n=70)使用糖尿病药物。
  • 时变血糖、胰岛素、HOMA-IR及SHBG与肌瘤诊断无关联。
  • 糖尿病与肌瘤诊断发生率降低28%相关(校正HR 0.72,95%CI 0.44-1.17),主要由使用二甲双胍的参与者驱动(校正HR 0.49,95%CI 0.21-1.12),但精度有限。
  • 按绝经状态分层后,较高的HOMA-IR和胰岛素与绝经前肌瘤诊断发生率增加相关,而与围绝经期无关。
  • 糖尿病与肌瘤的负相关在围绝经期最强。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Fibroids are noncancerous uterine tumors potentially associated with cardiovascular risk factors. OBJECTIVE: We aimed to examine prospectively associations of glucose, insulin, sex hormone-binding globulin (SHBG), and diabetes with incidence of fibroid diagnoses in midlife. METHODS: Participants in the Study of Women's Health Across the Nation (SWAN) cohort (n = 2570) reported fibroid diagnoses at enrollment (1996-1997) and 13 follow-up visits (1996-2013). At all visits, we measured glucose, insulin, and SHBG in fasting blood samples and calculated homeostatic model assessment for insulin resistance (HOMA-IR). Diabetes was defined using glucose levels, self-reported diabetes, or diabetes medication use. We used discrete-time survival models to estimate hazard ratios (HR) and 95% CI for associations of time-varying biomarkers and diabetes with incident fibroid diagnoses, adjusted for demographics and health care utilization. We also evaluated effect modification by menopausal status. RESULTS: At baseline, 2.7% of participants (n = 70) were using diabetes medication. Time-varying glucose, insulin, HOMA-IR, and SHBG were not associated with fibroid diagnosis. However, diabetes was associated with a 28% lower incidence of fibroid diagnosis (adjusted HR 0.72, 95% CI 0.44, 1.17), driven by participants using metformin (adjusted HR 0.49, 95% CI 0.21, 1.12), though precision was limited. After stratification by menopausal status, higher HOMA-IR and insulin were associated with greater incidence of fibroid diagnosis during premenopause but not perimenopause, while the inverse association between diabetes and fibroids was strongest during perimenopause. CONCLUSION: The effect of diabetes and biomarkers on fibroids may vary by menopausal status. Fibroid risk may increase with insulin resistance and decrease with diabetes treatment.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Mitro SD, Waetjen LE, Lee C, et al. Diabetes and Uterine Fibroid Diagnosis in Midlife: Study of Women's Health Across the Nation (SWAN). J Clin Endocrinol Metab. 2025. PMID: 39257183. doi:10.1210/clinem/dgae625

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。